MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

被引：0
|
作者：
Ly, Ina [1 ]
Cardona, Jonathan [2 ]
Beers, Andrew [2 ]
Chang, Ken [2 ]
Brown, James [2 ]
Reardon, David [3 ]
Arrillaga-Romany, Isabel [4 ]
Dietrich, Jorg [1 ]
Forst, Deborah [1 ]
Lee, Eudocia [3 ]
Jordan, Justin [5 ]
Nayak, Lakshmi [3 ]
Wen, Patrick [6 ]
Batchelor, Tracy [4 ]
Kalpathy-Cramer, Jayashree [7 ]
Gerstner, Elizabeth [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[6] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NIMG-68
引用
下载
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [21] Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
    Ney, Douglas E.
    Carlson, Julie A.
    Damek, Denise M.
    Gaspar, Laurie E.
    Kavanagh, Brian D.
    Kleinschmidt-DeMasters, B. K.
    Waziri, Allen E.
    Lillehei, Kevin O.
    Reddy, Krishna
    Chen, Changhu
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (01) : 135 - 143
  • [22] Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
    Douglas E. Ney
    Julie A. Carlson
    Denise M. Damek
    Laurie E. Gaspar
    Brian D. Kavanagh
    B. K. Kleinschmidt-DeMasters
    Allen E. Waziri
    Kevin O. Lillehei
    Krishna Reddy
    Changhu Chen
    Journal of Neuro-Oncology, 2015, 122 : 135 - 143
  • [23] Phase II trial of erlotinib with temozolomide and concurrent radiation therapy post-operatively in patients with newly diagnosed glioblastoma multiforme
    Pecreboom, DM
    Brewer, C
    Stevens, GHJ
    Suh, JH
    Toms, S
    Vogelbaum, MA
    Barnett, GH
    NEURO-ONCOLOGY, 2004, 6 (04) : 379 - 379
  • [24] Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
    Perez-Larraya, Jaime Gallego
    Ducray, Francois
    Chinot, Olivier
    Catry-Thomas, Isabelle
    Taillandier, Luc
    Guillamo, Jean-Sebastien
    Campello, Chantal
    Monjour, Annick
    Cartalat-Carel, Stephanie
    Barrie, Maryline
    Huchet, Aymeri
    Beauchesne, Patrick
    Matta, Mona
    Mokhtari, Karima
    Tanguy, Marie-Laure
    Honnorat, Jerome
    Delattre, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3050 - 3055
  • [25] Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
    Nghiemphu, Phioanh Leia
    Bahng, Hye Hyun
    Lai, Albert
    Faiq, Nadia
    Yong, William H.
    Green, Richard M.
    Polikoff, Jonathan
    Spier, Cynthia Elizabeth
    Iwamoto, Fabio Massaiti
    Lassman, Andrew B.
    Cloughesy, Timothy Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Chang, SM
    Lamborn, KR
    Malec, M
    Larson, D
    Wara, W
    Sneed, P
    Rabbitt, J
    Page, M
    Nicholas, MK
    Prados, MD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02): : 353 - 357
  • [27] A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter
    Faye, M. D.
    Sabri, S.
    De Robles, P.
    Agnihotram, R.
    Torres-Vasquez, A.
    Panet-Raymond, V.
    Shenouda, G.
    Souhami, L.
    Esaw, J.
    Abdulkarim, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S169 - S169
  • [28] A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
    Rosenfeld, M. R.
    Chamberlain, M. C.
    Grossman, S. A.
    Peereboom, D. M.
    Lesser, G. J.
    Batchelor, T. T.
    Desideri, S.
    Salazar, A. M.
    Ye, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA DURING CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE
    Ly, Ina
    Ou, Yangming
    Da, Xiao
    Batchelor, Tracy
    Kalpathy-Cramer, Jayashree
    Gerstner, Elizabeth
    NEURO-ONCOLOGY, 2016, 18 : 128 - 129
  • [30] RANDOMIZED PHASE II TRIAL OF TUMOR TREATING FIELDS PLUS RADIATION THERAPY PLUS TEMOZOLOMIDE COMPARED TO RADIATION THERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Limon, D.
    Bokstein, F.
    Blumenthal, D.
    Ben Harush, C.
    Ram, Z.
    Grossman, R.
    NEURO-ONCOLOGY, 2019, 21 : 86 - 86
12345